全文获取类型
收费全文 | 1745909篇 |
免费 | 132647篇 |
国内免费 | 8448篇 |
专业分类
耳鼻咽喉 | 22093篇 |
儿科学 | 56164篇 |
妇产科学 | 46986篇 |
基础医学 | 247606篇 |
口腔科学 | 49780篇 |
临床医学 | 158765篇 |
内科学 | 339643篇 |
皮肤病学 | 39283篇 |
神经病学 | 133567篇 |
特种医学 | 66091篇 |
外国民族医学 | 283篇 |
外科学 | 262852篇 |
综合类 | 50389篇 |
现状与发展 | 21篇 |
一般理论 | 533篇 |
预防医学 | 127227篇 |
眼科学 | 41718篇 |
药学 | 130090篇 |
78篇 | |
中国医学 | 7959篇 |
肿瘤学 | 105876篇 |
出版年
2021年 | 14266篇 |
2019年 | 15803篇 |
2018年 | 22239篇 |
2017年 | 17187篇 |
2016年 | 18577篇 |
2015年 | 21999篇 |
2014年 | 30004篇 |
2013年 | 41077篇 |
2012年 | 57335篇 |
2011年 | 60848篇 |
2010年 | 35935篇 |
2009年 | 33076篇 |
2008年 | 54780篇 |
2007年 | 58135篇 |
2006年 | 58665篇 |
2005年 | 55797篇 |
2004年 | 52775篇 |
2003年 | 50135篇 |
2002年 | 47980篇 |
2001年 | 93109篇 |
2000年 | 94977篇 |
1999年 | 78365篇 |
1998年 | 19946篇 |
1997年 | 17534篇 |
1996年 | 17373篇 |
1995年 | 17499篇 |
1994年 | 15983篇 |
1993年 | 14471篇 |
1992年 | 57828篇 |
1991年 | 55714篇 |
1990年 | 53339篇 |
1989年 | 51058篇 |
1988年 | 46382篇 |
1987年 | 45141篇 |
1986年 | 42397篇 |
1985年 | 40117篇 |
1984年 | 29378篇 |
1983年 | 24892篇 |
1982年 | 13865篇 |
1979年 | 25499篇 |
1978年 | 17528篇 |
1977年 | 14849篇 |
1976年 | 13829篇 |
1975年 | 14513篇 |
1974年 | 17601篇 |
1973年 | 16907篇 |
1972年 | 15664篇 |
1971年 | 14433篇 |
1970年 | 13415篇 |
1969年 | 12504篇 |
排序方式: 共有10000条查询结果,搜索用时 125 毫秒
1.
Kara S. Tanaka MD Veronica R. Andaya BA Steven W. Thorpe MD Kenneth R. Gundle MD James B. Hayden MD Yee-Cheen Duong MD Raffi S. Avedian MD David G. Mohler MD Lee J. Morse MD Melissa N. Zimel MD Richard J. O'Donnell MD Andrew Fang MD Robert Lor Randall MD Tina H. Tran BS Christin New BA Rosanna L. Wustrack MD other members of Study Group FORCE 《Journal of surgical oncology》2023,127(1):148-158
2.
S. Liu A. E. Patanwala J. M. Naylor N. Levy R. Knaggs J. A. Stevens B. Bugeja D. Begley K. E. Khor E. Lau R. Allen S. Adie J. Penm 《Anaesthesia》2023,78(10):1237-1248
Modified-release opioids are often prescribed for the management of moderate to severe acute pain following total hip and knee arthroplasty, despite recommendations against their use due to increasing concerns regarding harm. The primary objective of this multicentre study was to examine the impact of modified-release opioid use on the incidence of opioid-related adverse events compared with immediate-release opioid use, among adult inpatients following total hip or knee arthroplasty. Data for total hip and knee arthroplasty inpatients receiving an opioid analgesic for postoperative analgesia during hospitalisation were collected from electronic medical records of three tertiary metropolitan hospitals in Australia. The primary outcome was the incidence of opioid-related adverse events during hospital admission. Patients who received modified with or without immediate-release opioids were matched to those receiving immediate-release opioids only (1:1) using nearest neighbour propensity score matching with patient and clinical characteristics as covariates. This included total opioid dose received. In the matched cohorts, patients given modified-release opioids (n = 347) experienced a higher incidence of opioid-related adverse events overall, compared with those given immediate-release opioids only (20.5%, 71/347 vs. 12.7%, 44/347; difference in proportions 7.8% [95%CI 2.3–13.3%]). Modified-release opioid use was associated with an increased risk of harm when used for acute pain during hospitalisation after total hip or knee arthroplasty. 相似文献
3.
目的 比较腹腔镜和开腹手术治疗长径5~10 cm的中危胃间质瘤的安全性和有效性,并评估患者术后使用伊马替尼辅助治疗是否有明显益处。方法 回顾性分析2010年1月—2020年7月在南京大学医学院附属鼓楼医院接受手术治疗的72例长径在5~10 cm的中危胃间质瘤患者资料。其中腹腔镜手术组28例,开腹手术组44例。比较两组患者基本资料、病理特征、围手术期结果、住院总费用。对比术后使用和不使用伊马替尼辅助治疗的生存率。结果 开腹组和腹腔镜组临床病理特征差异无统计学意义(P>0.05)。腹腔镜组术后并发症发生率为32.1%(9/28),开腹组为52.3%(23/44),两组比较差异无统计学意义(P=0.094)。与开腹组相比,腹腔镜组总住院时间明显缩短[(12.5±3.2) d比(15.0±3.5) d,P=0.004];术后中位住院天数明显缩短(7.5 d 比 9.0 d,P=0.006);首次排气时间明显缩短(P=0.003)。中位随访时间58个月(13~129个月),期间未出现与肿瘤相关的死亡病例。开腹组有2例死亡,分别因乳腺癌和心脏病;腹腔镜组有1例死亡,死亡原因与胃间质瘤无关。72例患者中,40例术后接受伊马替尼辅助治疗,开腹组22例(50.0%),腹腔镜组18例(64.3%),两组接受伊马替尼辅助治疗的患者例数占比差异无统计学意义(χ2=1.414,P=0.234)。术后使用伊马替尼辅助治疗组总体生存率与未使用伊马替尼辅助治疗组相比差异有统计学意义 (P=0.015)。结论 与开腹手术相比,腹腔镜治疗长径在5~10 cm的中危胃间质瘤是一种安全有效的方法。实现R0切除的长径在5~10 cm的中危胃间质瘤患者术后使用伊马替尼辅助治疗未增加生存率,且未使用伊马替尼者未出现与肿瘤相关的死亡、复发及转移。 相似文献
4.
Maja Popovic Gorana Matovina-Brko Masa Jovic Lazar S Popovic 《World journal of clinical oncology》2022,13(1):28-38
Renal cell cancer (RCC) represents 2%-3% of all adulthood cancers and is the most common malignant neoplasm of the kidney (90%). In the mid-nineties of the last century, the standard of treatment for patients with metastatic RCC was cytokines. Sunititib and pazopanib were registered in 2007 and 2009, respectively, and have since been the standard first-line treatment for metastatic clear cell RCC (mccRCC). Renal cell cancer is a highly immunogenic tumor with tumor infiltrating cells, including CD8+ T lymphocytes, dendritic cells, natural killer cells (NK) and macrophages. This observation led to the design of new clinical trials in which patients were treated with immunotherapy. With the growing evidence that proangiogenic factors can have immunomodulatory effects on the host’s immune system, the idea of combining angiogenic drugs with immunotherapy has emerged, and new clinical trials have been designed. In the last few years, several therapeutic options have been approved [immunotherapy and immunotherapy/tyrosine kinase inhibitors (TKI)] for the first-line treatment of mccRCC. Nivolumab/ipilimumab is approved for the treatment of patients with inter mediate and poor prognoses. Several checkpoint inhibitors (pembrolizumab, nivolumab, avelumab) in combination with TKI (axitinib, lenvatinib, cabozan tinib) are approved for the treatment of patients regardless of their International mRCC Database Consortium prognostic group and PD-L1 expression. There is no specific and ideal biomarker that could help in selecting the ideal patient for the appropriate first-line treatment. 相似文献
5.
Rozhkov V. P. Trifonov M. I. Soroko S. I. 《Neuroscience and behavioral physiology》2022,52(3):383-394
Neuroscience and Behavioral Physiology - We present here results from analysis of the formation of brain bioelectrical activity in children and adolescents living in the northern region of Russia... 相似文献
6.
7.
Given that the global population of elderly individuals is expanding and the difficulty of recovery, hip fractures will be a huge challenge and a critical health issue for all of humanity. Although people have spent more time at home during the coronavirus disease 2019 (COVID-19) pandemic, hip fractures show no sign of abating. Extensive studies have shown that patients with hip fracture and COVID-19 have a multifold increase in mortality compared to those uninfected and a more complex clinical condition. At present, no detailed research has systematically analyzed the relationship between these two conditions and proposed a comprehensive solution. This article aims to systematically review the impact of COVID-19 on hip fracture and provide practical suggestions. We found that hip fracture patients with COVID-19 have higher mortality rates and more complicated clinical outcomes. Indirectly, COVID-19 prevents hip fracture patients from receiving regular medical treatment. With regard to the problems we encounter, we provide clinical recommendations based on existing research evidence and a clinical flowchart for the management of hip fracture patients who are COVID-19 positive. Our study will help clinicians adequately prepare in advance when dealing with such patients and optimize treatment decisions. 相似文献
9.
10.
Microbial co-infections are another primary concern in patients with coronavirus disease 2019 (COVID-19), yet it is an untouched area among researchers. Preliminary data and systematic reviews only show the type of pathogens responsible for that, but its pathophysiology is still unknown. Studies show that these microbial co-infections are hospital-acquired/nosocomial infections, and patients admitted to intensive care units with invasive mechanical ventilation are highly susceptible to it. Patients with COVID-19 had elevated inflammatory cytokines and a weakened cell-mediated immune response, with lower CD4+ T and CD8+ T cell counts, indicating vulnerability to various co-infections. Despite this, there are only a few studies that recommend the management of co-infections. 相似文献